Ronald A Lubet

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients
    Erick Roman-Perez
    Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, USA
    Breast Cancer Res 14:R51. 2012
  2. doi request reprint Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
  3. pmc Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
  4. doi request reprint Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
  5. ncbi request reprint Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
  6. doi request reprint Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012
  7. ncbi request reprint Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
  8. doi request reprint Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
  9. pmc Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Cancer Prev Res (Phila) 6:448-54. 2013
  10. doi request reprint Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Oncol Rep 25:1389-97. 2011

Detail Information

Publications23

  1. pmc Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients
    Erick Roman-Perez
    Department of Epidemiology, University of North Carolina at Chapel Hill, Campus Box 7435, Chapel Hill, NC 27599, USA
    Breast Cancer Res 14:R51. 2012
    ..We hypothesized that gene expression subtypes of breast cancer microenvironment can be defined and that these microenvironment subtypes have clinical relevance...
  2. doi request reprint Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis
    Ronald A Lubet
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:161-7. 2009
    ..Similarly, atorvastatin failed to alter the development of estrogen receptor-negative mammary carcinomas in a new animal model using bitransgenic mice (MMTV-Neu(+/-)/p53KO(+/-)), whereas bexarotene (250 mg/kg diet) was effective...
  3. pmc Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NIH, Bethesda, Maryland, USA
    Cancer Prev Res (Phila) 2:951-6. 2009
    ..These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis...
  4. doi request reprint Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    J Urol 183:1598-603. 2010
    ..We optimized agent testing in an in vivo bladder cancer model and determined the most sensitive, relevant protocol to test efficacy in clinical prevention trials...
  5. ncbi request reprint Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 5:1073-8. 2006
    ..Thus, R115777 was active in the prevention and therapy of these chemically induced mammary cancers, but was strikingly more effective in cancers with HaRas mutations...
  6. doi request reprint Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
    Oncol Rep 27:1400-6. 2012
    ..There was minimal overlap of efficacy. That is, models which were relatively susceptible to NSAIDs or COX-2 inhibitors tended not to be sensitive to Targretin and vice versa...
  7. ncbi request reprint Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:441-8. 2005
    ..Determination of serum IGF1 levels showed that treatment of rats with highly effective doses of Targretin at 272 mg/kg diet or at 60 or 20 mg/kg body wt/day by gavage caused significantly decreased serum IGF1 levels...
  8. doi request reprint Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 7:972-9. 2008
    ..Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone...
  9. pmc Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Cancer Prev Res (Phila) 6:448-54. 2013
    ..Thus, altering the dose of erlotinib retained most of its preventive and therapeutic efficacy, and based on prior clinical studies, is likely to reduce its toxicity...
  10. doi request reprint Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Oncol Rep 25:1389-97. 2011
    ..In particular, cell cycle genes related to the anaphase protein complex (APC) pathway, including CDC 20, cyclin B1, BUB1 and both of the Aurora kinases, were significantly decreased...
  11. ncbi request reprint Preventive Effects of NSAIDs, NO-NSAIDs, and NSAIDs Plus Difluoromethylornithine in a Chemically Induced Urinary Bladder Cancer Model
    Holly L Nicastro
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852
    Cancer Prev Res (Phila) 7:246-54. 2014
    ..Thus, naproxen and NO-naproxen were highly effective, whereas sulindac was moderately effective in the OH-BBN model at their HEDs. Cancer Prev Res; 7(2); 246-54. ©2013 AACR. ..
  12. doi request reprint Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA
    Int J Cancer 123:2254-9. 2008
    ..In summary, rosiglitazone over a wide dose range enhanced urinary bladder carcinogenesis in the OH-BBN model in rats...
  13. doi request reprint Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: is DIM a substitute for I3C?
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, NIH, NCI, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Oncol Rep 26:731-6. 2011
    ..In contrast, DIM had minimal effects in either model; arguing that administration of DIM is not analogous to administration of I3C...
  14. pmc Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Chem Biol Interact 182:22-8. 2009
    ..g., quinone reductase) is a surrogate for overall Phase II inducing (antioxidant) and potential anti-tumor activity...
  15. ncbi request reprint The utility of genetically altered mouse models for nutrition and cancer chemoprevention research
    Stephen D Hursting
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Mutat Res 576:80-92. 2005
    ....
  16. ncbi request reprint 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin
    Ronald A Lubet
    Division of Cancer Prevention, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Carcinogenesis 26:571-8. 2005
    ..The anti-apoptotic protein survivin was not expressed in normal bladder epithelium, but was variably expressed in cancers. FHIT and survivin expressions were similar in cancers from indomethacin-treated and non-treated mice...
  17. ncbi request reprint Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols
    Ronald A Lubet
    National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852, USA
    Mol Cancer Ther 6:2022-8. 2007
    ..The bioavailability of these tea polyphenols to different organ sites may contribute to the differing preventive efficacy of Polyphenon E against urinary bladder and mammary cancers...
  18. ncbi request reprint Can animal models help us select specific compounds for cancer prevention trials?
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Recent Results Cancer Res 166:71-87. 2005
    ....
  19. pmc The use of animal models for cancer chemoprevention drug development
    Vernon E Steele
    Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA
    Semin Oncol 37:327-38. 2010
    ..Whether validated or not, animal efficacy data remain central to the clinical trial decision-making process...
  20. pmc 6-C-(E-phenylethenyl)-naringenin suppresses colorectal cancer growth by inhibiting cyclooxygenase-1
    Haitao Li
    Authors Affiliations The Hormel Institute, University of Minnesota, Austin, Minnesota The National Institutes of Health, National Cancer Institute, Bethesda, Maryland and School of Biological Sciences, The University of Hong Kong, Hong Kong, China
    Cancer Res 74:243-52. 2014
    ..Taken together, COX-1 plays a critical role in human colorectal carcinogenesis, and this specific COX-1 inhibitor merits further investigation as a potential preventive agent against colorectal cancer...
  21. ncbi request reprint Chemoprevention of lung cancer in transgenic mice
    Ronald A Lubet
    Chemoprevention Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Chest 125:144S-7S. 2004
  22. ncbi request reprint Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice
    Richard Bachelier
    Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases NIH, Bethesda, MD 20892, USA
    Oncol Rep 14:1117-20. 2005
    ..The data also show that oophorectomy, if performed significantly prior to the time that tumors arise, appears to be quite effective...
  23. ncbi request reprint Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer
    Vernon E Steele
    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892 7322, USA
    Mutat Res 523:137-44. 2003
    ..As newer more specific drugs are developed with few adverse effects this important prevention strategy may become a reality...